From the Guidelines
The recommended dose of Qulipta (atogepant) for preventive treatment of episodic migraine is 10 mg, 30 mg, or 60 mg taken orally once daily. All three dosages have demonstrated efficacy in clinical trials, so the appropriate dose can be selected based on individual patient factors and response 1. Qulipta can be taken with or without food. For patients with severe renal impairment (creatinine clearance 15-29 mL/min) or those with certain liver conditions, the recommended dose should be reduced to 10 mg once daily. Patients taking strong CYP3A4 inhibitors should also use the 10 mg dose due to potential drug interactions. Qulipta works by blocking calcitonin gene-related peptide (CGRP) receptors, which are involved in migraine pathophysiology. This medication is specifically indicated for adults with episodic migraine (fewer than 15 headache days per month) and may take several weeks to reach full effectiveness, so patients should continue taking it daily even if they don't notice immediate benefits.
Some key points to consider when prescribing Qulipta include:
- The medication's efficacy in reducing the frequency and severity of migraine headaches
- The potential for drug interactions, particularly with strong CYP3A4 inhibitors
- The need to adjust the dose in patients with severe renal impairment or certain liver conditions
- The importance of patient education and engagement in the management of their migraine treatment plan
It's also important to note that Qulipta is just one of several treatment options available for the prevention of episodic migraine, and the choice of medication should be individualized based on patient-specific factors and preferences 1.
From the FDA Drug Label
The recommended dosage of QULIPTA for episodic migraine is 10 mg, 30 mg, or 60 mg taken once daily. The recommended dose of Qulipta (atogepant) for preventive treatment of episodic migraine is:
From the Research
Qulipta Dose for Episodic Migraine
The recommended dose of Qulipta (atogepant) for the preventive treatment of episodic migraine is:
- 10 mg, 30 mg, or 60 mg once daily 3
Efficacy of Qulipta
Key findings on the efficacy of Qulipta include:
- Reduction in mean number of migraine days per month across 12 weeks: -3.7 days with 10-mg atogepant, -3.9 days with 30-mg atogepant, -4.2 days with 60-mg atogepant, and -2.5 days with placebo 3
- Mean differences from placebo in the change from baseline: -1.2 days with 10-mg atogepant, -1.4 days with 30-mg atogepant, and -1.7 days with 60-mg atogepant (P<0.001 for all comparisons with placebo) 3
Time Course of Efficacy
The time course of efficacy of atogepant for the preventive treatment of migraine is:
- Atogepant demonstrated treatment benefits as early as the first full day after treatment initiation, and sustained efficacy across each 4-week interval during the 12-week treatment period 4
- Reductions in mean monthly migraine days ranged from -3.1 to -3.9 for atogepant vs -1.6 for placebo during weeks 1-4, and from -4.2 to -4.4 for atogepant vs -3.0 for placebo during weeks 9-12 4